Droperidol has comparable clinical efficacy against both nausea and vomiting

Area of Science:

• Anesthesiology
• Pharmacology
• Clinical Medicine

Background:

• Droperidol is often considered more effective for preventing postoperative nausea (PON) than postoperative vomiting (POV).
• The assumption of a short duration of action for droperidol is relevant for designing multi-drug antiemetic regimens.
• Understanding droperidol's efficacy and duration is crucial for optimizing postoperative care.

Purpose of the Study:

• To evaluate the comparative efficacy of droperidol in preventing postoperative nausea and vomiting.
• To assess the duration of action of droperidol in the early and late postoperative periods.
• To inform clinical decisions regarding antiemetic strategies.

Main Methods:

• A post hoc analysis of a large multicenter trial involving 1734 patients undergoing inhalation anesthesia.
• Patients were randomized to receive antiemetic interventions, including droperidol 1.25 mg versus placebo, in a factorial design.
• Significance was determined by non-overlapping confidence intervals and a risk ratio (RR) difference of at least 20%.

Main Results:

• Over 24 hours, droperidol reduced nausea from 42.9% to 32.0% (RR 0.75) and vomiting from 15.6% to 11.8% (RR 0.76).
• In the early postoperative period (0-2 hours), droperidol showed similar efficacy for nausea (RR 0.57) and vomiting (RR 0.56).
• In the late postoperative period (2-24 hours), efficacy for nausea (RR 0.83) and vomiting (RR 0.89) was similar but significantly less than in the early period.

Conclusions:

• Droperidol demonstrates equal effectiveness in preventing both postoperative nausea and vomiting.
• The duration of droperidol's antiemetic action is limited.
• These findings support the equal efficacy but short duration of droperidol, influencing its role in antiemetic regimens.